Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.

Phase 2UnknownNCT01019863

Centre de recherche du Centre hospitalier universitaire de Sherbrooke50 enrolled

Overview

Evaluation of the efficacy, tolerance, quality of life and cost effectiveness of the association of Oxaliplatin, Gemcitabine, Rituximab and Dexamethasone for treatment of patients with refractory or relapsing non-Hodgkin lymphoma.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Non-Hodgkin Lymphoma

Interventions

oxaliplatinDRUG

oxaliplatin 100mg/m2 + Rituxan 375 mg/m2 + Gemcitabine 1000mg/m2 every 2 weeks for 8 cycles

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients 18 years or above at the time of inclusion. 2. Documented CD20+ NHL, refractory or relapsing after first line chemotherapy. 3. No contraindication to Oxaliplatin, Gemcitabine, Dexamethasone or Rituximab. Exclusion Criteria: 1. Other types of non-Hodgkin lymphoma 2. Pregnancy and lactation. 3. Patient unable to give written informed consent. 4. Contra-indication ou intolerance to any of the components of the RGDOx chemotherapy.

Locations (2)

CHA Hôpital de l'Enfant-Jésus

Québec, Quebec, Canada

RECRUITING

CHUS Hopital Fleurimont

Sherbrooke, Quebec, Canada

RECRUITING

Outcomes

Primary Outcomes

Response rate to RGDOx in patients with relapsing or refractory NHL

Time frame: Within 3 months after chemotherapy (6-8 cycles)

Central Contacts

Anick Champoux, RN

CONTACT

819-346-1110 achampoux.chus@ssss.gouv.qc.ca

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.